Terman, Elizabeth
Sheade, Jori
Zhao, Fangyuan
Howard, Frederick M.
Jaskowiak, Nora
Tseng, Jennifer
Chen, Nan
Hahn, Olwen
Fleming, Gini
Huo, Dezheng
Nanda, Rita http://orcid.org/0000-0001-5248-0876
Funding for this research was provided by:
Foundation for the National Institutes of Health (NCI-SOAR Grant#1R25CA240134-01, P20CA233307, P20CA233307)
Pritzker School of Medicine (Summer Research Program 2021)
Article History
Received: 10 March 2023
Accepted: 5 April 2023
First Online: 29 April 2023
Declarations
:
: Dr. Nanda has received funding from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Gilead/Immunomedics, Merck, OBI Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sun Pharma, Taiho. She serves on the advisory board of AstraZeneca, BeyondSpring, Fujifilm, GE, Gilead, Infinity, iTeos, Merck, OBI, Oncosec, Sanofi, Seagen. Dr. Fleming serves as an institutional PI of an industry sponsored study for Roche, Iovance, Sermonix, Campugen, Celldex, Corcept, AstraZeneca, Molecular Templates, Astellas, K group beta, and Pfizer. The following companies supported a CME event organized by Dr. Fleming: DSI, Merck, Caris, Eisai, AZ. The remaining authors have no relevant financial or non-financial interests to disclose.